三生国健:与辉瑞就707项目达成合作,许可方实际收取的销售里程碑款项和特许权使用费存在不确定性

界面
22 May

三生国健5月22日发布公告,公司股票交易连续两个交易日内收盘价格涨幅偏离值累计超过30%,连续四个交易日内日收盘价格涨幅偏离值累计超过100%,属于股票交易异常波动情形。公司及公司的关联方三生制药和沈阳三生制药有限责任公司(简称“沈阳三生”,以下合称“许可方”)共同授予被许可方辉瑞公司(Pfizer Inc.)(简称“被许可方”)在许可区域(即除中国大陆以外的其他国家和地区)及领域(即人类和兽医...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10